Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latanoprost/Timolol Dosing Frequency in POAG
NCT04098861Phase 4Unknown
- Sponsor
- Hospital Canselor Tuanku Muhriz
- Start
- Jan 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of latanoprost + timolol in primary open-angle glaucoma (POAG) (2 arms), sponsored by Hospital Canselor Tuanku Muhriz. Primary endpoint: Intraocular pressure reduction at 4 weeks. Status: unknown.
02
Drugs
latanoprost + timolol
03
Conditions
primary open-angle glaucoma (POAG)
Beyond the preview
Go deeper on NCT04098861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04098861.